Results 11 to 20 of about 48,653 (304)
Tardive Dyskinesia and Treatment Approaches [PDF]
Psikiyatride Güncel Yaklaşımlar, 2018 Tardive dyskinesia is an iatrogenic movement disorder with an incompletely determined etiology. Involuntary movements can effect oral, lingual, facial, corporal muscles and can be permanent. Tardive dyskinesia is one of the most important side effects of
Mehmet Emin Demirkol +3 more
doaj +2 more sources
Geriatric Nursing, 1982 Tardive dyskinesia is now widely recognised as a neurological disorder associated with the administration of antipsychotic drugs. Prevalence is higher among the elderly. The cause is unknown but the hypothesis of hypersensitivity of post-synaptic dopamine receptors is currently generally accepted.
V A, Portnoi, J E, Johnson
core +7 more sources
Movement Disorders, 2019 AbstractLevodopa‐induced dyskinesia (LID) represents a significant source of discomfort for people with Parkinson's disease (PD). It negatively affects quality of life, it is associated with both motor and nonmotor fluctuations, and it brings an increased risk of disability, balance problems, and falls.
M Angela, Cenci +4 more
core +4 more sources
Geriatrics, Gerontology and AgingDyskinesia affects the limbs, trunk, and head and is more prevalent in people with Parkinson’s disease (PD) and a history of falls. More evidence about the effects of dyskinesia on postural control, balance, gait, and fall risk could help improve the ...
Lucas Henrique Caetano Carmona dos Santos +7 more
doaj +2 more sources
Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia [PDF]
Frontiers in Neurology, 2022 BackgroundThe Unified Dyskinesia Rating Scale (UDysRS) evaluates dyskinesia in patients with Parkinson's disease (PD). A minimal clinically important change (MCIC)—the smallest change in a treatment outcome that a patient considers important—remains ...
Rajesh Pahwa +8 more
doaj +2 more sources
ERJ Open Research, 2021 Objectives Disease-specific, well-defined and validated clinical outcome measures are essential in designing research studies. Poorly defined outcome measures hamper pooling of data and comparisons between studies.
Florian Gahleitner +13 more
doaj +1 more source
Could New Generations of Sensors Reshape the Management of Parkinson’s Disease?
Clinical and Translational Neuroscience, 2021 Parkinson's disease (PD) is a chronic neurologic disease that has a great impact on the patient’s quality of life. The natural course of the disease is characterized by an insidious onset of symptoms, such as rest tremor, shuffling gait, bradykinesia ...
Oleg S. Levin +3 more
doaj +1 more source
Proceedings of the 4th BEAT-PCD Conference and 5th PCD Training School
BMC Proceedings, 2020 Primary ciliary dyskinesia (PCD) is an inherited ciliopathy leading to chronic suppurative lung disease, chronic rhinosinusitis, middle ear disease, sub-fertility and situs abnormalities.
Laura E. Gardner +24 more
doaj +1 more source
Frontiers in Neurology, 2021 After long-term use of levodopa, Parkinson's patients almost inevitably develop dyskinesia, a kind of drug side effect manifesting as uncontrollable choreic movements and dystonia, which could be crippling yet have limited therapeutic options ...
Yi Wu +9 more
doaj +1 more source
Case Reports in Ophthalmology, 2022 General anesthesia is usually selected when patients cannot remain still during surgery with local anesthesia. However, damage to the lungs from positive pressure ventilation under general anesthesia is a major concern in patients with Parkinson’s ...
Takafumi Suzuki +5 more
doaj +1 more source